Hemispherx Biopharma’s CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology

by Barry101 | May 8, 2019 | Press Release

OCALA, Fla., May 08, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with investors and industry representatives to discuss the...

Hemispherx Links Stanford's ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization

by Barry101 | May 6, 2019 | Press Release

OCALA, Fla., May 06, 2019 — Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – and whose product portfolio...

Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program

by Barry101 | Apr 30, 2019 | Press Release

OCALA, Fla., April 30, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen...

Hemispherx Biopharma’s CEO to Present at Planet MicroCap Showcase 2019

by Barry101 | Apr 25, 2019 | Press Release

OCALA, Fla., April 25, 2019 — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase...

Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer

by Barry101 | Apr 22, 2019 | Press Release

OCALA, Fla., April 22, 2019 — (NYSE American: HEB) – Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced the appointment of Ellen Lintal as the...

Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab

by Barry101 | Apr 2, 2019 | Press Release

OCALA, Fla., April 02, 2019 — (NYSE American: HEB) – Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx’ experimental drug...